GlobeNewswire: BioQ Pharma Contains the last 10 of 20 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T14:03:07ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2017/11/20/1197474/0/en/BioQ-Pharma-and-Sophos-Biotech-Enter-into-Strategic-Partnership-for-Post-Operative-Analgesia-Therapy-in-Italy.html?f=22&fvtc=4&fvtv=25973BioQ Pharma and Sophos Biotech Enter into Strategic Partnership for Post-Operative Analgesia Therapy in Italy2017-11-20T13:30:00Z<![CDATA[ROME and SAN FRANCISCO, Nov. 20, 2017 (GLOBE NEWSWIRE) -- BioQ Pharma Incorporated (“BioQ”) and Sophos Biotech S.r.l. (“Sophos”), both specialty pharmaceutical companies, today announced a strategic partnership agreement under which BioQ will supply and Sophos will commercialize a proprietary treatment for post-operative pain management in Italy.]]>https://www.globenewswire.com/news-release/2017/09/05/1107826/0/en/Cooper-Pharma-and-BioQ-Pharma-Enter-into-Strategic-Partnership-for-Ropivacaine-ReadyfusOR-in-Morocco.html?f=22&fvtc=4&fvtv=25973Cooper Pharma and BioQ Pharma Enter into Strategic Partnership for Ropivacaine ReadyfusOR in Morocco2017-09-05T15:14:43Z<![CDATA[CASABLANCA, Morocco and SAN FRANCISCO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Cooper Pharma (“Cooper”) and BioQ Pharma Incorporated (“BioQ”), both specialty pharmaceutical companies, today announced a strategic partnership agreement to commercialize Ropivacaine ReadyfusOR in Morocco for the treatment of post-surgical pain in adults.]]>https://www.globenewswire.com/news-release/2017/08/23/1091446/0/en/STADA-Australia-and-BioQ-Pharma-Enter-into-Strategic-Partnership-to-Commercialize-Three-Ready-to-Use-Infusion-Products.html?f=22&fvtc=4&fvtv=25973STADA Australia and BioQ Pharma Enter into Strategic Partnership to Commercialize Three Ready-to-Use Infusion Products 2017-08-23T12:00:00Z<![CDATA[SYDNEY, Australia and SAN FRANCISCO, Aug. 23, 2017 (GLOBE NEWSWIRE) -- STADA Pharmaceuticals Australia Pty Ltd (“STADA”) and BioQ Pharma Incorporated (“BioQ”), both specialty pharmaceutical companies, today announced a strategic agreement to commercialize three ready-to-use infusion pharmaceuticals in Australia and New Zealand.]]>https://www.globenewswire.com/news-release/2017/08/15/1084750/0/en/BioQ-Pharma-Secures-up-to-55-Million-in-Combined-Debt-and-Equity-Financing-from-Madryn-Asset-Management.html?f=22&fvtc=4&fvtv=25973BioQ Pharma Secures up to $55 Million in Combined Debt and Equity Financing from Madryn Asset Management2017-08-15T12:00:00Z<![CDATA[SAN FRANCISCO and NEW YORK, Aug. 15, 2017 (GLOBE NEWSWIRE) -- BioQ Pharma Incorporated (“BioQ”), a privately held specialty pharmaceutical company, today announced that it has secured new financing of up to $55 million from Madryn Asset Management, LP (“Madryn”), an alternative asset management firm focused on investments in innovative healthcare companies. The proceeds of the investment will be used by BioQ to support product commercialization, scale-up manufacturing and operations, and continue new product development.]]>https://www.globenewswire.com/news-release/2017/05/16/985398/0/en/BioQ-Pharma-to-Present-at-the-UBS-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=25973BioQ Pharma to Present at the UBS Global Healthcare Conference2017-05-16T11:30:00Z<![CDATA[SAN FRANCISCO, May 16, 2017 (GLOBE NEWSWIRE) -- BioQ Pharma Incorporated, a specialty pharmaceutical company, announced today that the Company will be presenting at the UBS Global Healthcare Conference to be held in New York City from May 22nd to May 24th, 2017.]]>https://www.globenewswire.com/news-release/2017/04/04/954104/0/en/BioQ-Pharma-and-Lunatus-Add-a-Third-Infusion-Pharmaceutical-to-Commercial-Agreement-Covering-Arabian-Gulf-Area-and-Middle-East.html?f=22&fvtc=4&fvtv=25973BioQ Pharma and Lunatus Add a Third Infusion Pharmaceutical to Commercial Agreement Covering Arabian Gulf Area and Middle East2017-04-04T12:30:00Z<![CDATA[SAN FRANCISCO and DUBAI, United Arab Emirates, April 04, 2017 (GLOBE NEWSWIRE) -- BioQ Pharma Incorporated, a specialty pharmaceutical company, and Lunatus, a company focused on building and developing profitable pharmaceutical brands in Arabian Gulf and Middle East markets, today announced the addition of a third ready-to-use infusible pharmaceutical product to their existing strategic distribution, supply, and commercial agreement.  Adding this third drug expands BioQ Pharma and Lunatus’ previously signed agreement covering ropivacaine and propofol infusion pharmaceutical products in Saudi Arabia, the United Arab Emirates, Qatar and Kuwait.]]>https://www.globenewswire.com/news-release/2017/03/30/947110/0/en/BioQ-Pharma-to-Present-at-the-16th-Annual-Needham-Healthcare-Conference.html?f=22&fvtc=4&fvtv=25973BioQ Pharma to Present at the 16th Annual Needham Healthcare Conference2017-03-30T13:00:00Z<![CDATA[SAN FRANCISCO, March 30, 2017 (GLOBE NEWSWIRE) -- BioQ Pharma Incorporated, a specialty pharmaceutical company, announced today that the Company will be presenting at the 16th Annual Needham Healthcare Conference to be held in New York City on April 4th and 5th, 2017.]]>https://www.globenewswire.com/news-release/2017/03/17/940558/0/en/BioQ-Pharma-to-Present-at-27th-Annual-Oppenheimer-Healthcare-Conference.html?f=22&fvtc=4&fvtv=25973BioQ Pharma to Present at 27th Annual Oppenheimer Healthcare Conference2017-03-17T11:00:00Z<![CDATA[SAN FRANCISCO, March 17, 2017 (GLOBE NEWSWIRE) -- BioQ Pharma Incorporated, a specialty pharmaceutical company, announced today that the Company will be presenting at the 27th Annual Oppenheimer Healthcare Conference to be held in New York City on March 21st and 22nd, 2017.]]>https://www.globenewswire.com/news-release/2017/03/14/936242/0/en/BioQ-Pharma-Receives-Australian-Regulatory-Approval-for-Ropivacaine-ReadyFusOR.html?f=22&fvtc=4&fvtv=25973BioQ Pharma Receives Australian Regulatory Approval for Ropivacaine ReadyFusOR2017-03-14T12:00:00Z<![CDATA[SAN FRANCISCO, March 14, 2017 (GLOBE NEWSWIRE) -- BioQ Pharma Incorporated (“the Company”), a specialty pharmaceutical company, today announced that the Australian Therapeutic Goods Administration (TGA) has approved the Company’s Ropivacaine ReadyFusOR for the treatment of post-surgical pain in adults via continuous peripheral nerve block and continuous wound infiltration.  With well over two million surgical procedures annually, the market opportunity for post-surgical pain therapies in Australia is estimated to be more than A$500 million.]]>https://www.globenewswire.com/news-release/2016/12/06/895460/0/en/BioQ-Pharma-Enters-into-Strategic-Partnership-with-Galen-Limited-to-Commercialize-Three-Ready-to-Use-Infusion-Products-in-the-United-Kingdom-and-Ireland.html?f=22&fvtc=4&fvtv=25973BioQ Pharma Enters into Strategic Partnership with Galen Limited to Commercialize Three Ready-to-Use Infusion Products in the United Kingdom and Ireland2016-12-06T13:30:00Z<![CDATA[SAN FRANCISCO, Dec. 06, 2016 (GLOBE NEWSWIRE) -- BioQ Pharma Incorporated, a specialty pharmaceutical company, today announced the signing of a strategic distribution, supply and development agreement to commercialize three infusion pharmaceuticals in the United Kingdom and the Republic of Ireland with Galen Limited, a specialty pharmaceutical company marketing products within the UK, Ireland, Europe and the US in therapeutic areas such as pain management, gastroenterology and female health.]]>